{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:48Z","timestamp":1793148348368,"version":"4.5.0"},"reference-count":25,"publisher":"The Journal of Rheumatology","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,10,14]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze the efficacy and safety of anifrolumab, a monoclonal antibody targeting the type I interferon receptor subunit 1, as a therapeutic option in patients with refractory cutaneous dermatomyositis (DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with DM presenting with cutaneous involvement refractory to different immunosuppressive treatments were enrolled. The Cutaneous Dermatomyositis Disease Area and Severity Index activity (CDASI-A) was used to evaluate the evolution of skin involvement. Manual muscle test-8 (MMT-8) and patient global assessment (PtGA) scores were collected, to evaluate both muscle involvement and patients\u2019 quality of life. We registered the changes in glucocorticoid (GC) daily dose, to explore the possible GC-sparing effect of the drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 4 patients (50% female, mean age 60 years). At enrollment, they showed an active cutaneous disease (mean CDASI-A 27\/100), mean MMT-8 of 67.5\/80, mean daily dose of GC of 10 mg of prednisone, and mean PtGA value of 7.5\/10. After treatment, all these variables improved, with mean CDASI-A decreasing to 8.75\/100, MMT-8 increasing to 71.3\/80, daily GC dose decreasing to 4 mg, and PtGA decreasing to 1.5\/10.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The data we collected showed a significant reduction in CDASI-A values. Further, our results showed an improvement in muscle involvement and in patients\u2019 perception of disease burden. Finally, a GC-sparing effect and a good global safety profile of anifrolumab were observed, thus confirming anifrolumab as a new valid therapeutic option in patients with refractory cutaneous DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0773","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:25:29Z","timestamp":1761999929000},"page":"180-185","source":"Crossref","is-referenced-by-count":4,"title":["Anifrolumab Therapy in Dermatomyositis: New Insights From Refractory Patients"],"prefix":"10.3899","volume":"53","author":[{"given":"Linda","family":"Carli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cavagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6407-6213","authenticated-orcid":false,"given":"Chiara","family":"Cardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Fattorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Zampaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Diomedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elenia","family":"Laurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"2026070105051066000_53.2.180.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225"},{"key":"2026070105051066000_53.2.180.2","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/ced.14689","article-title":"The chameleon rash: a review of the polyphenotypic dermatoses of dermatomyositis","volume":"46","author":"Connolly","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2026070105051066000_53.2.180.3","doi-asserted-by":"crossref","first-page":"117443","DOI":"10.1016\/j.cca.2023.117443","article-title":"Polymyositis and dermatomyositis biomarkers","volume":"547","author":"Xu","year":"2023","journal-title":"Clin Chim Acta"},{"key":"2026070105051066000_53.2.180.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2006.07.001"},{"key":"2026070105051066000_53.2.180.5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.autrev.2017.07.016","article-title":"How I treat idiopathic patients with inflammatory myopathies in the clinical practice","volume":"16","author":"Cavagna","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2026070105051066000_53.2.180.6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.55563\/clinexprheumatol\/styx9u","article-title":"The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events","volume":"39","author":"Gisondi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2026070105051066000_53.2.180.7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14726"},{"key":"2026070105051066000_53.2.180.8","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/rheumatology\/keaa184","article-title":"Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis","volume":"59","author":"Delvino","year":"2020","journal-title":"Rheumatology"},{"key":"2026070105051066000_53.2.180.9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/ITT.S381472","article-title":"Dermatomyositis: practical guidance and unmet needs","volume":"13","author":"Cassard","year":"2024","journal-title":"ImmunoTargets Ther"},{"key":"2026070105051066000_53.2.180.10","doi-asserted-by":"crossref","first-page":"103455","DOI":"10.1016\/j.autrev.2023.103455","article-title":"Idiopathic inflammatory myopathies\u2014the burden of disease: cohort analysis focusing on damage and comorbidities","volume":"22","author":"Campar","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026070105051066000_53.2.180.11","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/rheumatology\/keab851","article-title":"Cardiovascular events in adult polymyositis and dermatomyositis: a meta-analysis of observational studies","volume":"61","author":"Xiong","year":"2022","journal-title":"Rheumatology"},{"key":"2026070105051066000_53.2.180.12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-018-1687-8","article-title":"Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study","volume":"20","author":"van Dijkhuizen","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2026070105051066000_53.2.180.13","doi-asserted-by":"crossref","first-page":"103686","DOI":"10.1016\/j.autrev.2024.103686","article-title":"The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis","volume":"23","author":"Castellini","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2026070105051066000_53.2.180.14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002864"},{"key":"2026070105051066000_53.2.180.15","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000261"},{"key":"2026070105051066000_53.2.180.16","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30076-1"},{"key":"2026070105051066000_53.2.180.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2026070105051066000_53.2.180.18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2026070105051066000_53.2.180.19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ced\/llae476","article-title":"Anifrolumab use in refractory dermatomyositis: a case report and literature review","volume":"50","author":"Claudio-Oliva","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2026070105051066000_53.2.180.20","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: A multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026070105051066000_53.2.180.21","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4744"},{"key":"2026070105051066000_53.2.180.22","first-page":"e66704","article-title":"A novel treatment for skin manifestations in dermatomyositis: a case report","volume":"16","author":"Srinivasa Murthy","year":"2024","journal-title":"Cureus"},{"key":"2026070105051066000_53.2.180.23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026070105051066000_53.2.180.24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9900"},{"key":"2026070105051066000_53.2.180.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2016.06.006"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:13:00Z","timestamp":1782907980000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,1]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3899\/jrheum.2025-0773"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0773","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}